Significance and considerations of early diagnosis and treatment for improving height outcomes in children with achondroplasia
LI Li, XIONG Feng
Department of Endocrinology, Children's Hospital of Chongqing Medical University/National Clinical Research Center for Child Health and Disorders/Ministry of Education Key Laboratory of Child Development and Disorders/Chongqing Key Laboratory of Pediatric Metabolism and Inflammatory Diseases, Chongqing 400014, China
Abstract Achondroplasia (ACH) is a common skeletal dysplasia in children, primarily caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. These mutations disrupt the process of endochondral ossification in different types of bones, including long bones of the limbs and vertebrae. Children with ACH typically present with short stature and may experience severe multi-system complications. The diagnosis of ACH is based on typical clinical manifestations, imaging features, and genetic testing results. Treatment options mainly include pharmacological interventions and surgical procedures aimed at improving height, as well as symptomatic management for associated complications. This article discusses both prenatal and clinical diagnostic approaches for ACH, as well as treatment strategies focused on enhancing height, aiming to deepen the understanding of this condition.
LI Li,XIONG Feng. Significance and considerations of early diagnosis and treatment for improving height outcomes in children with achondroplasia[J]. CJCP, 2025, 27(3): 262-268.
LI Li,XIONG Feng. Significance and considerations of early diagnosis and treatment for improving height outcomes in children with achondroplasia[J]. CJCP, 2025, 27(3): 262-268.
Savarirayan R, Ireland P, Irving M, et al. International consensus statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia[J]. Nat Rev Endocrinol, 2022, 18(3): 173-189. PMID: 34837063. DOI: 10.1038/s41574-021-00595-x.
Constantinides C, Landis SH, Jarrett J, et al. Quality of life, physical functioning, and psychosocial function among patients with achondroplasia: a targeted literature review[J]. Disabil Rehabil, 2022, 44(21): 6166-6178. PMID: 34403286. DOI: 10.1080/09638288.2021.1963853.
Stender M, Pimenta JM, Cheung M, et al. Comprehensive literature review on the prevalence of comorbid conditions in patients with achondroplasia[J]. Bone, 2022, 162: 116472. PMID: 35728791. DOI: 10.1016/j.bone.2022.116472.
Onesimo R, Sforza E, Bedeschi MF, et al. How pain affect real life of children and adults with achondroplasia: a systematic review[J]. Eur J Med Genet, 2023, 66(11): 104850. PMID: 37758167. DOI: 10.1016/j.ejmg.2023.104850.
Cormier-Daire V, AlSayed M, Alves I, et al. Optimising the diagnosis and referral of achondroplasia in Europe: European Achondroplasia Forum best practice recommendations[J]. Orphanet J Rare Dis, 2022, 17(1): 293. PMID: 35897040. PMCID: PMC9327303. DOI: 10.1186/s13023-022-02442-2.
Savarirayan R, Rossiter JP, Hoover-Fong JE, et al. Best practice guidelines regarding prenatal evaluation and delivery of patients with skeletal dysplasia[J]. Am J Obstet Gynecol, 2018, 219(6): 545-562. PMID: 30048634. DOI: 10.1016/j.ajog.2018.07.017.
Bedeschi MF, Mora S, Antoniazzi F, et al. The clinical management of children with achondroplasia in Italy: results of clinician and parent/caregiver surveys[J]. J Endocrinol Invest, 2024, 47(2): 345-356. PMID: 37466810. DOI: 10.1007/s40618-023-02151-y.
Hoover-Fong J, McGready J, Schulze K, et al. A height-for-age growth reference for children with achondroplasia: expanded applications and comparison with original reference data[J]. Am J Med Genet A, 2017, 173(5): 1226-1230. PMID: 28374958. DOI: 10.1002/ajmg.a.38150.
Kanazawa H, Tanaka H, Inoue M, et al. Efficacy of growth hormone therapy for patients with skeletal dysplasia[J]. J Bone Miner Metab, 2003, 21(5): 307-310. PMID: 12928832. DOI: 10.1007/s00774-003-0425-7.
Pinto G, Cormier-Daire V, Le Merrer M, et al. Efficacy and safety of growth hormone treatment in children with hypochondroplasia: comparison with an historical cohort[J]. Horm Res Paediatr, 2014, 82(6): 355-363. PMID: 25323764. DOI: 10.1159/000364807.
Miccoli M, Bertelloni S, Massart F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis[J]. Horm Res Paediatr, 2016, 86(1): 27-34. PMID: 27355624. DOI: 10.1159/000446958.
Hertel NT, Ekl?f O, Ivarsson S, et al. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial[J]. Acta Paediatr, 2005, 94(10): 1402-1410. PMID: 16299871. DOI: 10.1111/j.1651-2227.2005.tb01811.x.
Fafilek B, Bosakova M, Krejci P. Expanding horizons of achondroplasia treatment: current options and future developments[J]. Osteoarthritis Cartilage, 2022, 30(4): 535-544. PMID: 34864168. DOI: 10.1016/j.joca.2021.11.017.
Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial[J]. Lancet, 2020, 396(10252): 684-692. PMID: 32891212. DOI: 10.1016/S0140-6736(20)31541-5.
Savarirayan R, Tofts L, Irving M, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study[J]. Genet Med, 2021, 23(12): 2443-2447. PMID: 34341520. PMCID: PMC8327889. DOI: 10.1038/s41436-021-01287-7.
Savarirayan R, Wilcox WR, Harmatz P, et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Child Adolesc Health, 2024, 8(1): 40-50. PMID: 37984383. DOI: 10.1016/S2352-4642(23)00265-1.
Song SH, Kim SE, Agashe MV, et al. Growth disturbance after lengthening of the lower limb and quantitative assessment of physeal closure in skeletally immature patients with achondroplasia[J]. J Bone Joint Surg Br, 2012, 94(4): 556-563. PMID: 22434475. DOI: 10.1302/0301-620X.94B4.28375.
Balci H?, Anarat FB, Bayram S, et al. Does the technique of limb lengthening affect physeal growth in patient with achondroplasia? Comparison of the simultaneous and consecutive tibia and femur lengthening with external fixators[J]. J Pediatr Orthop B, 2023, 32(1): 60-65. PMID: 36125888. DOI: 10.1097/BPB.0000000000001011.
Hoover-Fong J, Scott CI, Jones MC, et al. Health supervision for people with achondroplasia[J]. Pediatrics, 2020, 145(6): e20201010. PMID: 32457214. DOI: 10.1542/peds.2020-1010.
